CMP
TEVA icon

Coston McIsaac & Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Coston McIsaac & Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-438
Closed -$9K – 835
2024
Q4 		$9K Sell
438
-122
-22% -$2.22K ﹤0.01% 508
2024
Q3 		$10 Hold
560
– – ﹤0.01% 501
2024
Q2 		$9K Sell
560
-163
-23% -$2.51K ﹤0.01% 490
2024
Q1 		$10K Hold
723
– – ﹤0.01% 476
2023
Q4 		$7K Hold
723
– – ﹤0.01% 527
2023
Q3 		$7K Hold
723
– – ﹤0.01% 509
2023
Q2 		$5K Hold
723
– – ﹤0.01% 611
2023
Q1 		$6K Hold
723
– – ﹤0.01% 569
2022
Q4 		$6 Hold
723
– – ﹤0.01% 572
2022
Q3 		$5K Hold
723
– – ﹤0.01% 515
2022
Q2 		$5K Buy
+723
New +$6.3K ﹤0.01% 353

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Coston McIsaac & Partners's TEVA Position: Q1 2025 in Review

Coston McIsaac & Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 438 shares — an estimated $9K sold.

Coston McIsaac & Partners first reported a position in TEVA in Q2 2022 and held it in 11 quarters. The position peaked at $10K in Q1 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Coston McIsaac & Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coston McIsaac & Partners sold 438 Teva Pharmaceuticals shares in Q1 2025, an estimated $9K.
  • Coston McIsaac & Partners first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Coston McIsaac & Partners's Teva Pharmaceuticals position peaked at $10K in Q1 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Coston McIsaac & Partners's 13F filing for Q1 2025, filed 13 May 2025.